Search research articles
Contact Us
Filters
Showing results (21-30 of 112) with videos related to
Page
of 12
Sort By:
Wiener Klinische Wochenschrift
|
July 1, 2005
Major response and clinical benefit following third-line treatment for Bellini duct carcinoma
Negar Fakhrai, Andrea Haitel, Csilla Balassy, et al.
Cancer Treatment Reviews
|
June 1, 2012
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers
Daniel Castellano, Alain Ravaud, Manuela Schmidinger, et al.
Annals of Medicine
|
May 10, 2022
Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy
Christoph Minichsdorfer, Andreas Gleiss, Marie-Bernadette Aretin, et al.
Cancer Treatment Reviews
|
September 25, 2016
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy
Emiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, et al.
Clinical Genitourinary Cancer
|
November 5, 2023
Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma
Andreas Bruchbacher, Johannes Franke, Arman Alimohammadi, et al.
Anticancer Research
|
May 16, 2009
Management of cardiac adverse events occurring with sunitinib treatment
Manuela Schmidinger, Andja Bojic, Ursula M Vogl, et al.
International Journal of Surgical Pathology
|
July 7, 2023
Metastatic Translocated Renal Cell Carcinoma in a Kidney Transplant Patient - a Case Report and Review of the Literature
Johannes Kläger, Manuela Schmidinger, André Oszwald, et al.
Current Opinion in Urology
|
May 9, 2021
Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis
Fahad Quhal, Keiichiro Mori, Mesut Remzi, et al.
Current Opinion in Urology
|
November 1, 2021
Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis
Fahad Quhal, Keiichiro Mori, Harun Fajkovic, et al.
Current Opinion in Urology
|
March 20, 2021
Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?
Manuela Schmidinger, Irene Resch, Harun Fajkovic, et al.
Page
of 12
Search research articles
Search
Showing results (21-30 of 112) with videos related to
Sort By:
Page
of 12
Wiener Klinische Wochenschrift
|
July 1, 2005
Major response and clinical benefit following third-line treatment for Bellini duct carcinoma
Negar Fakhrai, Andrea Haitel, Csilla Balassy, et al.
Cancer Treatment Reviews
|
June 1, 2012
Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key concepts and the impact of clinical biomarkers
Daniel Castellano, Alain Ravaud, Manuela Schmidinger, et al.
Annals of Medicine
|
May 10, 2022
Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy
Christoph Minichsdorfer, Andreas Gleiss, Marie-Bernadette Aretin, et al.
Cancer Treatment Reviews
|
September 25, 2016
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy
Emiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, et al.
Clinical Genitourinary Cancer
|
November 5, 2023
Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma
Andreas Bruchbacher, Johannes Franke, Arman Alimohammadi, et al.
Anticancer Research
|
May 16, 2009
Management of cardiac adverse events occurring with sunitinib treatment
Manuela Schmidinger, Andja Bojic, Ursula M Vogl, et al.
International Journal of Surgical Pathology
|
July 7, 2023
Metastatic Translocated Renal Cell Carcinoma in a Kidney Transplant Patient - a Case Report and Review of the Literature
Johannes Kläger, Manuela Schmidinger, André Oszwald, et al.
Current Opinion in Urology
|
May 9, 2021
Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis
Fahad Quhal, Keiichiro Mori, Mesut Remzi, et al.
Current Opinion in Urology
|
November 1, 2021
Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis
Fahad Quhal, Keiichiro Mori, Harun Fajkovic, et al.
Current Opinion in Urology
|
March 20, 2021
Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma?
Manuela Schmidinger, Irene Resch, Harun Fajkovic, et al.
Page
of 12